Cargando…

Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study

In Myanmar, hepatitis C virus (HCV) infection prevalence is 2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naing, Cho, Sitt, Than, Aung, Aye TD, Aung, Kyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	4900
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554122/ https://www.ncbi.nlm.nih.gov/pubmed/26222859 http://dx.doi.org/10.1097/MD.0000000000001234

Ejemplares similares

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
por: Janczewska, Ewa, et al.
Publicado: (2015)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
por: Kwon, Jung Hyun, et al.
Publicado: (2009)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
por: Asselah, Tarik, et al.
Publicado: (2016)

Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma: A meta-analysis
por: Li, Chien-Feng, et al.
Publicado: (2020)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
por: Choi, Sang Bun, et al.
Publicado: (2011)

Case report: Ribavirin and vitamin A in a severe case of measles
por: Bichon, Amandine, et al.
Publicado: (2017)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Peginterferon Alfa-2a Is Associated with Elevations in Alanine Aminotransferase at the End of Treatment in Chronic Hepatitis C Patients with Sustained Virologic Response
por: Tseng, Chih-Wei, et al.
Publicado: (2014)

Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience
por: Al Ashgar, Hamad, et al.
Publicado: (2008)

Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
por: Rodriguez-Torres, M, et al.
Publicado: (2010)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience
por: Abd-Elsalam, Sherief, et al.
Publicado: (2020)

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
por: Heo, Nae-Yun, et al.
Publicado: (2013)

Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report
por: Huang, Chung-Feng, et al.
Publicado: (2016)

CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study
por: Lee, I-Cheng, et al.
Publicado: (2013)

Increased Baseline Proinflammatory Cytokine Production in Chronic Hepatitis C Patients with Rapid Virological Response to Peginterferon Plus Ribavirin
por: Par, Gabriella, et al.
Publicado: (2013)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
por: Hofmann, Wolf Peter, et al.
Publicado: (2015)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
por: Artico, Simara, et al.
Publicado: (2012)

Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil
por: Barcaui, Halime Silva, et al.
Publicado: (2013)

Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis
por: Wang, Yinhua, et al.
Publicado: (2020)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
por: Mangia, Alessandra, et al.
Publicado: (2017)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Prevalence and Risk Factors of Hypertension in Myanmar: A Systematic Review and Meta-Analysis
por: Naing, Cho, et al.
Publicado: (2014)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran
por: Mehrazmay, Alireza, et al.
Publicado: (2013)

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013)

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4
por: Al Ashgar, Hamad, et al.
Publicado: (2009)

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
por: Hayashi, Norio, et al.
Publicado: (2014)

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
por: Ide, Kazuki, et al.
Publicado: (2016)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
por: Hayashi, Norio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4piam6l5405k6feiufvko4tvsv